BLUE BELL, Pa. -- Blue Bell, Pennsylvania will soon be home to PRA Health Sciences' largest office worldwide. PRA, a leading global Contract Research Organization (CRO), is relocating employees from its Horsham and Fort Washington locations into new modern Class A+ office space in Blue Bell. The new office opened this week and marks the first phase of the relocation plan.
"This is an exciting time for us at PRA," said Harris Koffer, President of the Strategic Solutions Group at PRA. "This move speaks to the continued robust growth of PRA Health Sciences and our commitment to our employees, clients, and the community."
The new facility, at 721 Arbor Way, offers cutting edge office design elements, staff workspace benefits, state-of-the-art shared tenant conference space, and a fitness center. The building's Leadership in Energy and Environmental Design (LEED) Silver Certification process is underway.
"We are very proud of this beautiful new facility and what it will mean for PRA Health Sciences," said Tami Klerr, Executive Vice President, Business Development. "This new office space allows our full service, late phase, and Strategic Solutions groups to fully integrate into one cohesive Philadelphia area location."
The second phase of the move is expected to take place in the second quarter of 2015. Once completed, the new facility in Blue Bellwill house approximately 860 PRA employees and will include more than 148,000 square feet.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 10,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. As a top five CRO, PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.